Skip to content

US · CMMB · BIOTECHNOLOGY

Chemomab Therapeutics Ltd. (CMMB) intrinsic value and stock valuation

$1.19as of 2026-11-21 · Mkt cap 10.77M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Chemomab Therapeutics Ltd. DCF and intrinsic value

InvestorsCraft values CMMB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CMMB’s statements →

Chemomab Therapeutics Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Tel Aviv, TA 6158002 chemomab.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-8.99M
20112025
Free cash flow
-$-11.22M
20152025
Total equity
$12.3M+2.7% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-9.57M-$-14.74M-$-25.46M-$-28.53M-$-12.37M
Net income-$-8.99M-$-13.95M-$-24.22M-$-27.65M-$-12.48M
EPSd-$-1.41M-$-3.11M-$-8.24M-$-9.74M-$-4.82M
Operating cash flow-$-11.22M-$-15.46M-$-23.55M-$-20.29M-$-12.38M
Capital expenditure-$0.00$0.00-$0.00-$-70K-$-240K
Free cash flow-$-11.22M-$-15.46M-$-23.55M-$-20.36M-$-12.62M
Total assets$13.8M$17M$22.2M$43.1M$64.4M
Total debt$0.00$320K$390K$210K$340K
Net debt-$-7.56M-$-5.75M-$-8.9M-$-13.3M-$-14.34M
Total equity$12.3M$13.5M$17M$36.2M$61.5M
Cash and short-term investments$10.4M$14.3M$19.8M$39.9M$61.2M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$50K$70K$60K$30K
Gross profit$0.00-$-50K-$-70K-$-60K-$-30K
Research and development expenses$5.83M$10K$18.4M$17M$6.33M
Selling, general and administrative expenses$3.73M$0.00$7.08M$11.6M$6.03M
Other expenses$0.00$14.7M$0.00$0.00$0.00
Operating expenses$9.57M$14.7M$25.5M$28.5M$12.4M
Cost and expenses$9.57M$14.7M$25.5M$28.5M$12.4M
Interest income$570K$800K$1.24M$350K$0.00
Interest expense$0.00$0.00$0.00$350K$110K
Depreciation and amortization$70K$50K$70K$60K$30K
Ebitda-$-9.5M-$-13.96M-$-25.39M-$-28.48M-$-12.33M
Operating income-$-9.57M-$-14.74M-$-25.46M-$-28.53M-$-12.37M
Total other income/expenses, net$570K$790K$1.24M$350K-$-110K
Income before tax-$-8.99M-$-13.95M-$-24.22M-$-28.18M-$-12.48M
Income tax expense$0.00$0.00$0.00-$-530K$0.00
Net income-$-8.99M-$-13.95M-$-24.22M-$-27.65M-$-12.48M
Weighted average shares outstanding$6.38M$4.49M$2.94M$2.84M$2.59M
Weighted average diluted shares outstanding$6.38M$4.49M$2.94M$2.84M$2.59M
Balance sheet
20252024202320222021
Cash and short-term investments$10.4M$14.3M$19.8M$39.9M$61.2M
Net receivables$3.06M$260K$290K$460K$180K
Inventory$0.00$0.00$0.00$0.00-$-1.35M
Total current assets$13.4M$16M$20.9M$41.7M$62.7M
Property, plant and equipment, net$180K$540K$690K$590K$700K
Goodwill and intangible assets$0.00$10K$10K$0.00$10K
Long-term investments$0.00$0.00$0.00$0.00$60K
Total non-current assets$390K$920K$1.25M$1.33M$1.67M
Total assets$13.8M$17M$22.2M$43.1M$64.4M
Accounts payable$480K$670K$520K$1.69M$1.34M
Short-term debt$0.00$230K$150K$120K$210K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.48M$3.22M$4.84M$6.75M$2.65M
Long-term debt$0.00$210K$320K$90K$240K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$210K$320K$90K$240K
Capital lease obligations$0.00$320K$390K$210K$340K
Total liabilities$1.48M$3.43M$5.15M$6.84M$2.89M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-111.62M-$-102.62M-$-88.68M-$-63.82M-$-36.17M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$0.00$0.00
Total equity$12.3M$13.5M$17M$36.2M$61.5M
Total investments$2.8M$8.2M$10.5M$26.4M$46M
Total debt$0.00$320K$390K$210K$340K
Net debt-$-7.56M-$-5.75M-$-8.9M-$-13.3M-$-14.34M
Cash flow statement
20252024202320222021
Net income-$-9.07M-$-14.01M-$-24.16M-$-27.54M-$-12.49M
Depreciation and amortization$70K$50K$70K$60K$30K
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-2.86M-$-2.12M-$-950K$3.99M-$-1.95M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-180K$150K-$-1.17M$350K$1.18M
Net cash provided by operating activities-$-11.22M-$-15.46M-$-23.55M-$-20.29M-$-12.38M
Investments in property, plant and equipment-$0.00$0.00-$0.00-$-70K-$-240K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$5.43M$2.31M$15.8M$19.5M-$-45.22M
Common stock issued$7.21M$9.91M$3.49M$410K$58.7M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$7.21M$9.91M$3.49M-$-800K$61.1M
Net change in cash$1.42M-$-3.22M-$-4.23M-$-47.57M$55.8M
Cash at end of period$7.56M$6.15M$9.37M$13.6M$61.2M
Operating cash flow-$-11.22M-$-15.46M-$-23.55M-$-20.29M-$-12.38M
Capital expenditure-$0.00$0.00-$0.00-$-70K-$-240K
Free cash flow-$-11.22M-$-15.46M-$-23.55M-$-20.36M-$-12.62M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Chemomab Therapeutics Ltd.

        Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.

        CEO
        Adi Mor George
        Employees
        12
        Beta
        0.64

        Explore

        Frequently asked questions

        What is the intrinsic value of Chemomab Therapeutics Ltd. (CMMB)?

        InvestorsCraft does not currently publish an intrinsic value for CMMB. How the IC value is calculated.

        Is CMMB undervalued?

        InvestorsCraft does not publish an undervaluation signal for CMMB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.